Suppr超能文献

[人类肿瘤干细胞检测]

[Human tumor stem cell assay].

作者信息

Inoue K, Arakawa M, Ogawa M

出版信息

Gan To Kagaku Ryoho. 1982 Apr;9(4):599-605.

PMID:7184417
Abstract

Human tumor stem cell assay is an in vitro colony-forming technique. Double soft agar layers are used for culture tumor cells and cell lethality is judged by the numbers of colony formation in this assay. Single-cell suspension made from various malignant materials in cancer patients is placed in culture after exposing to various anticancer agents for one hour and incubated for two weeks. Antitumor effects of various anticancer agents against individual patients are evaluated by % inhibition of colony formation. Of 57 tumor specimens 42 (74%) formed at least five colonies per plate (per 0.5 x 10(6) cells). The colony-forming rates of various malignancies are as follows: breast cancer 14/15 (93%), ovarian cancer 8/10 (80%), stomach cancer 5/13 (38%), sarcoma 4/5 (80%), lung cancer 1/4 (25%), colon cancer 3/3, each of pancreas cancer, leukemia and primary unknown adenocarcinoma 2/2, malignant lymphoma 1/1. The median plating efficiency (number of colonies/number of nucleated cells plated) is 0.02% (range: 0.001-0.3%). High correlation between human tumor stem cell assay results and response of an individual patient's tumor to chemotherapy is reported by Salmon and Von Hoff. Human tumor stem cell assay is useful tool for the high prediction of chemosensitivity response.

摘要

人肿瘤干细胞检测是一种体外集落形成技术。双层软琼脂用于培养肿瘤细胞,通过该检测中的集落形成数量判断细胞杀伤力。将癌症患者各种恶性材料制成的单细胞悬液在接触各种抗癌剂1小时后进行培养,并孵育两周。通过集落形成抑制率评估各种抗癌剂对个体患者的抗肿瘤作用。在57个肿瘤标本中,42个(74%)每平板(每0.5×10⁶个细胞)形成至少5个集落。各种恶性肿瘤的集落形成率如下:乳腺癌14/15(93%),卵巢癌8/10(80%),胃癌5/13(38%),肉瘤4/5(80%),肺癌1/4(25%),结肠癌3/3,胰腺癌、白血病和原发性不明腺癌各为2/2,恶性淋巴瘤1/1。中位接种效率(集落数/接种的有核细胞数)为0.02%(范围:0.001 - 0.3%)。Salmon和Von Hoff报道人肿瘤干细胞检测结果与个体患者肿瘤对化疗的反应之间存在高度相关性。人肿瘤干细胞检测是预测化疗敏感性反应的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验